Wize Pharma

About Wize Pharma

Wize Pharma, Inc. (formerly known as OphthaliX, Inc.) is a clinical-stage biopharmaceutical company currently focused on the treatment of ophthalmic disorders, including dry eye syndrome (DES). Wize has in-licensed certain rights to purchase, market, sell and distribute a formula known as LO2A, a drug developed for the treatment of DES, and other ophthalmological illnesses, including Conjunctivochalasis (CCH) and Sjogren's syndrome (Sjogren's). LO2A is currently registered and marketed by its inventor in Germany and Switzerland for the treatment of DES, in Hungary for the treatment of DES and CCH and in the Netherlands for the treatment of DES and Sjogren's. Wize's strategy involves engaging local or multinational distributors to handle the distribution of LO2A, with the goal of becoming a leading company in its field.

LEADERSHIP:

CEO and CFO: Or Eisenberg

COO: Noam Danenberg

PRODUCTS:

All Products